Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of CDA-2 for the Treatment of IPSS Lower/Intermediate-risk Myelodysplastic Syndrome Patients: a Multi-centered Prospective Open Study

NCT03335943 is registered in ClinicalTrials.gov with Chinese Society of Hematology as lead sponsor.

NCT NCT03335943
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03335943 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of CDA-2 for the Treatment of IPSS Lower/Intermediate-risk Myelodysplastic Syndrome Patients: a Multi-centered Prospective Open Study
Lead sponsor
Chinese Society of Hematology
Phase
Phase 4
Overall status
Unknown status
Start date
December 1, 2017
Completion date
December 1, 2020
Enrollment
800 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndrome (mds)